Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-12-26

Clinical Trial Update: A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial update for ocrelizumab in primary progressive multiple sclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Multiple Sclerosis, Primary Progressive | Phase 3 | Status: COMPLETED | Results posted: 2017-12-26